Table 5.
Effect of Androgen Deprivation Therapy in a Subset on Laboratory Analysis
| Measure | Baseline | 3 Months | 1 Year |
|---|---|---|---|
| Insulin, μIU/mL | 8.5 (3.5 to 11.3) | 14.4* (8.4 to 19.7) | 7.2.0 to 12.3) |
| Glucose, mg/dL | 96 (79 to 118) | 101* (99 to 133) | 96 (81 to 102) |
| HOMAIR | 1.4 (0.7 to 1.7) | 3.5* (2.0 to 3.9) | 1.7 (1.2 to 2.4) |
| Total cholesterol, mg/dL | 148 (113 to 201) | 215* (135 to 220) | 163 (110 to 191) |
| HDL cholesterol, mg/dL | 41 (32 to 58) | 51 (43 to 64) | 41 (38 to 59) |
| LDL cholesterol, mg/dL | 95 (54 to 127) | 138* (69 to 152) | 110 (57 to 123) |
| Triglycerides, mg/dL | 75 (72 to 144) | 103 (85 to 124) | 93 (71 to 115) |
| hs‐CRP, mg/dL | 0.3 (0.2 to 1.3) | 1.1* (0.4 to 1.8) | 0.6 (0.4 to 2.2) |
| Estradiol, pg/mL | 23.1 (16.7 to 31.3) | 5.0* (5.0 to 14.9) | 27.8 (17.2 to 31.1) |
| Testosterone, ng/dL | 346 (158 to 738) | 13* (4 to 23) | 462 (353 to 565) |
Data are presented as median (interquartile range). HOMAIR indicates homeostatic model assessment insulin resistance; hs‐CRP, high‐sensitivity C‐reactive protein.
*
P<0.05, compared with baseline.
*
P=0.068, compared with baseline.